These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 28860885)

  • 1. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to osimertinib.
    Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
    J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib.
    Malapelle U; Ricciuti B; Baglivo S; Pepe F; Pisapia P; Anastasi P; Tazza M; Sidoni A; Liberati AM; Bellezza G; Chiari R; Metro G
    Recent Results Cancer Res; 2018; 211():257-276. PubMed ID: 30069773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-Generation
    Sullivan I; Planchard D
    Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating
    Mazza V; Cappuzzo F
    Appl Clin Genet; 2017; 10():49-56. PubMed ID: 28794650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Liao BC; Lin CC; Lee JH; Yang JC
    Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
    Mountzios G
    Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turning
    Hirsh V
    Ther Adv Med Oncol; 2018; 10():1758834017753338. PubMed ID: 29383041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.